Your browser doesn't support javascript.
loading
Vaccines for COVID-19: Where do we stand in 2021?
Sharma, Ketaki; Koirala, Archana; Nicolopoulos, Katrina; Chiu, Clayton; Wood, Nicholas; Britton, Philip N.
  • Sharma K; National Centre for Immunisation Research and Surveillance, Westmead, NSW, Australia; Sydney Medical School, The University of Sydney, NSW, Australia.
  • Koirala A; National Centre for Immunisation Research and Surveillance, Westmead, NSW, Australia; Sydney Medical School, The University of Sydney, NSW, Australia; Department of Infectious Diseases, Nepean Hospital, Penrith, NSW, Australia.
  • Nicolopoulos K; National Centre for Immunisation Research and Surveillance, Westmead, NSW, Australia.
  • Chiu C; National Centre for Immunisation Research and Surveillance, Westmead, NSW, Australia; Sydney Medical School, The University of Sydney, NSW, Australia.
  • Wood N; National Centre for Immunisation Research and Surveillance, Westmead, NSW, Australia; Sydney Medical School, The University of Sydney, NSW, Australia.
  • Britton PN; Sydney Medical School, The University of Sydney, NSW, Australia; Department of Infectious Diseases and Microbiology, The Children's Hospital at Westmead, NSW, Australia. Electronic address: Philip.Britton@health.nsw.gov.au.
Paediatr Respir Rev ; 39: 22-31, 2021 Sep.
Article en En | MEDLINE | ID: mdl-34362666
As of July 2021, over 3 billion doses of a COVID-19 vaccines have been administered globally, and there are now 19 COVID-19 vaccines approved for use in at least one country. Several of these have been shown to be highly effective both in clinical trials and real-world observational studies, some of which have included special populations of interest. A small number of countries have approved a COVID-19 vaccine for use in adolescents or children. These are laudable achievements, but the global vaccination effort has been challenged by inequitable distribution of vaccines predominantly to high income countries, with only 0.9% of people in low-income countries having received at least one dose of a COVID-19 vaccine. Addressing this inequity is of critical importance and will result in better control of SARS-CoV-2 globally. Other challenges include: the reduced protection from COVID-19 vaccines against some strains of SARS-CoV-2, necessitating the development of variant specific vaccines; and uncertainties around the duration of protection from vaccine-induced immunity.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Observational_studies Límite: Adolescent / Child / Humans Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Observational_studies Límite: Adolescent / Child / Humans Idioma: En Año: 2021 Tipo del documento: Article